This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Linlin Nie: Innovator in CDK Inhibitors
Introduction
Linlin Nie is a notable inventor based in Dongguan, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as cyclin-dependent kinase (CDK) inhibitors. His work focuses on addressing critical health issues related to inflammation and cell proliferation diseases.
Latest Patents
Linlin Nie holds a patent for "2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof." This invention provides compounds that act as small-molecule inhibitors of CDK, specifically targeting CDK 4 and CDK 6. The novel compounds developed by Nie have the potential to be used in treating various diseases associated with inflammation and abnormal cell growth. He has 1 patent to his name.
Career Highlights
Linlin Nie is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the pharmaceutical sector. His research and development efforts are aimed at creating effective therapeutic solutions that can significantly impact patient care.
Collaborations
Some of Linlin Nie's coworkers include Bing Liu and Yingjun Zhang, who contribute to the collaborative environment at Sunshine Lake Pharma Co., Ltd. Their combined expertise enhances the company's research capabilities and fosters innovation.
Conclusion
Linlin Nie's work in developing CDK inhibitors represents a significant advancement in the field of medicinal chemistry. His contributions have the potential to lead to new treatments for serious health conditions, showcasing the importance of innovation in the pharmaceutical industry.